C4X Discovery Holdings PLC (AIM:C4XD) CEO Clive Dix speaks to Thomas Warner from Proactive after releasing half-year results for the six months ending 31 January 2023.
Dix gives his highlights from the interim results before turning his focus to what he describes as a "slight pivot" to anti-inflammatory treatments.
C4X has a portfolio of anti-inflammatory targets, including a molecule for COPD, and four or five new anti-inflammatory targets in the pipeline, which will be revealed in due course.